3. 3
Antibiotic Use and
Resistance
• Strong epidemiological evidence that
antibiotic use in humans and animals
associated with increasing resistance.
• Sub therapeutic dosing encourages resistant
mutants to emerge; conversely, rapid
bactericidal activity discourages.
• Presence of b-lactamase producing
organisms.
• Abuse of the usage of antibiotics.
• Defective patient compliance.
4. 4
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
It was produced originally to reduce the
development of drug-resistant bacteria.
DELTACLAV is supplied in the new
recommended concentrations ratios
228.5
457
Ratio of 1:7
5. 5
DESCRIPTION:
DELTACLAV is an oral antibacterial
combination consisting of the semi-
synthetic antibiotic amoxicillin and the
lactamase inhibitor, clavulanate
potassium (the potassium salt of
clavulanic acid).
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
6. 8
After oral administration of single
doses:
Peak concentrations occurred
approximately 1 hour after the dose.
Approximately 50% to 70% of the
amoxicillin and approximately 25% to
40% of the clavulanic acid are excreted
unchanged in urine during the first 6
hours.
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
7. 10
Gram Positive Aerobes:
Staphylococcus aureus (lactamase and non
lactamase producing).
Enterococcus faecalis.
Staphylococcus epidermidis (lactamase
and non lactamase producing).
Staphylococcus saprophyticus (lactamase
and non lactamase producing).
Streptococcus pneumoniae.
Streptococcus pyogenes.
Streptococcus viridans group.
DELTACLAV (BacteriologicalDELTACLAV (Bacteriological
spectrumspectrum
8. 11
Gram Negative Aerobes:
Enterobacter species
Escherichia coli (lactamase and non lactamase producing)
Haemophilus influenzae (lactamase and non lactamase
producing)
Klebsiella species (All known strains are lactamase producing)
Moraxella catarrhalis (lactamase and non lactamase
producing)
Eikenella corrodens (lactamase and non lactamase producing)
Neisseria gonorrhoeae (lactamase and non lactamase
producing)
Proteus mirabilis (lactamase and non lactamase producing)
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
9. 12
Anaerobic Bacteria:
Bacteroides species, including
Bacteroides fragilis (lactamase and non
lactamase producing).
Fusobacterium species (lactamase and
non lactamase producing).
Peptostreptococcus species.
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
11. 14
INDICATIONS AND USAGE:
DELTACLAV is indicated in the treatment of
infections caused by susceptible strains of the
designated organisms in the conditions
listed below:
Lower Respiratory Tract Infections caused
by lactamase producing strains of H.
influenzae and M. catarrhalis.
Otitis Media caused by lactamase producing
strains of H. influenzae and M. catarrhalis.
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
12. 15
Sinusitis caused by lactamase producing strains
of H. influenzae and M. catarrhalis.
Skin and Skin Structure Infections caused by
lactamase producing strains of S. aureus,
E. coli, and Klebsiella species.
Urinary Tract Infections caused by lactamase
producing strains of E. coli, Klebsiella species,
and Enterobacter species.
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
14. 17
DOSAGE AND ADMINISTRATION:
Neonates and infants aged <12 weeks (3
months):
The recommended dose of DELTACLAV
is 30 mg/kg/day divided q12h, based
on the amoxicillin component.
DELTACLAVDELTACLAV
(Amoxicillin / Clavulanate potassium)
15. 18
DOSAGE AND ADMINISTRATION
Children:
-Otitis media, recurrent sinusitis,
lower respiratory tract infections,
and more severe infections 45
mg/kg/day q12h.
-Less severe infections 25
mg/kg/day q12h.
16. 19
CONCLUSIONS:
In comparison with the original formulation
administered tid for 10 days in the treatment of
AOM in children, the new formulation administered
bid for 10 days provides at least equivalent efficacy
and causes substantially less diarrhea.
78.8
86.5
0
10
20
30
40
50
60
70
80
90
Old Conc. New Conc.
Eradication %
Diarrhoea
Hoberman A, Paradise JL, Burch DJ, Valinski WA, Hedrick JA, Aronovitz GH,
Drehobl MA, Rogers JM.
18. 22
The new recommended concentrations.
The recommended 1st
line therapy by the
American Academy of Pediatrics in AOM.
Effective eradication of Upper and Lower
respiratory tract infective bacteria.
High bactericidal activity against resistant
bacteria resulting in 1st
time success.
Palatable banana taste with no rejection.
Affordable and competitive price.
DELTACLAVDELTACLAV (why)(why)
(Amoxicillin / Clavulanate potassium)
